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a b s t r a c t
Background: Severity of PD is usually assessed by means of the motor and disability-based Hoehn and
Yahr staging (HY), or clinician and patient global perceptions. Scores of more detailed assessments, as the
MDS-UPDRS, have not been translated to a grading that allows assignment of score sections to severity
levels. The objective of the present study is to determine cut-off points for PD severity levels based on the
MDS-UPDRS.
Methods: International, observational study. Applied assessments were: HY, MDS-UPDRS, Clinical
Impression for Severity Index, and Clinical and Patient Global Impression of Severity. The coincidence in
severity level (mild, moderate, severe) of at least two clinical classiﬁcations plus the patient's gradation
was considered “the criterion of severity”. Cut-off values for each MDS-UPDRS subscale was determined
by triangulation of: 1) percentile 90 of the subscale total score; 2) receiver operating characteristic (ROC)
analysis; and 3) ordinal logistic regression (OLR) model.
Results: Sample was composed of 452 consecutive PD patients without dementia, 55.3% males, age
65.1 ± 10.7 years and PD duration 8.7 ± 6.3 years. All HY stages were represented. The “criterion”,
classiﬁed 275 patients (60.8% of the sample) as: mild PD, 149 (54.2%); moderate, 82 (29.8%); and severe,
44 (16%). The following MDS-UPDRS cut-off points between mild/moderate and moderate/severe levels
were found: Part 1: 10/11 and 21/22; Part 2: 12/13 and 29/30; Part 3: 32/33 and 58/59; and Part 4: 4/5
and 12/13.
Conclusion: Cut-off points to classify PD patients as mild, moderate, or severe on the basis of their MDS-
UPDRS scores are proposed.
© 2014 Elsevier Ltd. All rights reserved.
1. Introduction
Parkinson's disease (PD) is a progressive neurodegenerative
disorder that clinically evolves over time from subtle non-speciﬁc
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non-motor manifestations of the premotor phase to the most
advanced stages in which patients are severely disabled. Progres-
sive disability is due to the combination of motor and non-motor
problems and related complications that increase in number and
severity throughout the course of the disease making the clinical
management more complex and affecting patients' quality of life
and independence [1e3].
Since the publication of the Hoehn and Yahr staging [4], mea-
sures to evaluate PD have evolved to comprehensive evaluations as,
for example, the Movement Disorder Society-Uniﬁed Parkinson's
Disease Rating Scale (MDS-UPDRS) [5] and the Non-Motor Symp-
toms Scale [6] or to assessments focused on a speciﬁc aspect such as
the Parkinson's Fatigue Scale [7] and the Parkinson's Disease
Dyskinesia Scale [8], among others. However, with the increasing
complexity of the disorder there is an increased difﬁculty to
determine the severity of the disease in a pragmatic and easily
understandable manner [9] and a combination of several global
self-reported and administered scales may be needed to approach
this objective.
Global measures have the advantage of providing concise in-
formation on the overall health state and can be useful for patients
selection (for example, cases with “mild disease” for a clinical trial)
and classiﬁcation (for example, assignment of a “very dependent”
level for receiving social assistance). In short, the distribution of
patients in such categories as mild, moderate, and severe, helps to
determine in a pragmatic manner their global health status, facil-
itates the communication, and allows the decision making process.
The most frequently used global assessment for PD is the Hoehn
and Yahr staging (HY) [4,10]. It is based on the disability resulting
from motor impairment and balance dysfunction, but does not
inform about some motor features and non-motor manifestations.
It is widely used for description of PD patients groups and case
selection for studies.
The generic Clinical Global Impression (CGI) [11] is a global
measure mainly applied in psychiatry, but also used in PD as an
outcome into clinical trials and other kind of studies. The CGI has
two main components, respectively focused on severity (CGIS) and
change (CGIC). The CGI has been criticized as inconsistent and too
general [12], but is widely used. The CGIS can be adapted for pa-
tients self-assessment (PGIS), a strategy allowing comparisons be-
tween rater-based and patient-based evaluation [12].
A recent approach to global evaluation of PD is the Clinical
Impression of Severity Index for PD (CISI-PD), a speciﬁc instrument
based on the global clinical impression on four relevant aspects of
PD: motors signs, disability, motor complications, and cognitive
impairment, a combination that explained 92% of the CGIS variance
[13]. The CISI-PD summarizes the evaluation carried out through
the interview, examination, and application of other assessments.
The present study was aimed at determining, using agreed
levels of severity among these professional- and patient-based
generic scales, the cut-off points for the MDS-UPDRS subscales
that could determine levels of disease severity of useful clinical
application.
2. Methods
2.1. Design
Multicenter, international, observational, cross-sectional study.
2.2. Patients
Consecutive patients with diagnosis of PD by a neurologist with expertise in
movement disorders, according to international criteria [14], were recruited. Pa-
tients suffering for other chronic disabling conditions impeding or interfering with
the evaluation of PD impact were excluded from the study. Patients unable to
directly answering written questionnaires were helped by a trained person out of
the patient's relationships and of the usual health professionals attending them.
Patients with moderate or severe cognitive deterioration, according to MDS-UPDRS
Part I e item 1 equal or greater than 3 and CISI-PD Cognition 4 or higher, were not
included in the analysis.
Each participant site obtained approval from the local Ethics Committee or
Institutional Review Board and patients had to give their signed consent to partic-
ipate in the study.
2.3. Assessments
In addition to demographic and PD historical information, the following as-
sessments were applied:
MDS-UPDRS Spanish version [5,15], a comprehensive scale composed of four
parts: Part IeNon-Motor Experiences of Daily Living, which includes thirteen items:
six rater-based and seven for patient self-assessment; Part II eMotor experiences of
daily living, with 13 patient-based items; Part III eMotor examination, including 18
items (33 scores); and Part IV e Motor complications, formed of six items on
dyskinesia and ﬂuctuations. Each item scores from 0 (normal) to 4 (severe) and for
each part, total scores are obtained from the sum of the corresponding item scores.
HY original version, that classiﬁes the course of PD in ﬁve stages [4,10].
CISI-PD [13,16], an instrument that provides a clinical estimate of PD severity
based on four outstanding PD aspects: motor signs, disability, motor complications,
and cognitive status. Each domain scores from 0 (normal) to 6 (very severe) and the
total score ranges from 0 to 24 points.
Global Impression of Severity. The 7-option clinician-based (CGIS) [11] and a 6-
option patient-based global impression of severity (PGIS, with the option “severe”
representing the collapse of the “markedly ill” and “severely ill”options that may be
difﬁcult to differentiate for patients) were included in the respective case report
forms.
2.4. Data analysis
Descriptive statistics (central tendency and dispersion measures; proportions)
were applied to characterize the variables in the sample. Levodopa-equivalent daily
dose was calculated according to Tomlinson et al., 2010 [17].
Concordance among the four global evaluations was estimated by means of the
Kendall's coefﬁcient of concordance. Given the different structure of the four scales,
a value 0.60 was considered satisfactory. Percentage of agreement between the
scales was also determined.
The global evaluations were transformed to three severity categories e mild,
moderate, and severe e according to previous studies or response options wording:
HY classiﬁcation (stages 1 and 2, mild; stage 3, moderate; and stages 4 and 5, severe)
[10]; CISI-PD (1e7, mild; 8e14, moderate; 15, severe) [16]; CGIS (2e3, mild; 4,
moderate; 5e7, severe); and PGIS (1e2, mild; 3, moderate; 4e5, severe) (Table 1).
The coincidence in degree of severity of at least two of the three clinical clas-
siﬁcations plus the patient's gradation was adopted as “the criterion of severity” for
this study. Comparison between groups broken down by these severity levels was
carried out with the KruskaleWallis test. Bonferroni correction for multiple com-
parisons was applied.
Cut-off values for each MDS-UPDRS subscale by each severity level were
determined by means of: 1) percentile 90 of the subscale total score; 2) receiver
operating characteristic (ROC) analysis; and 3) ordinal logistic regression (OLR)
model, calculating the probability curves for each category of severity and the cut-off
points between these curves. The OLR was applied to ascertain the relationship
between a continuous variable independent (the MDS-UPDRS subscales) and a
dependent variable of ordinal type (the severity levels classiﬁcation), allowing to
obtain the cut-off points of the independent variable model logit associatedwith the
‘k’ (three, in the present study) categories of the dependent variable. As foreseeably
the three described methods would not coincide in their results, a triangulation by
average of the three corresponding values was planned to estimate the value most
probably close to the true cut-off point for each situation.
3. Results
The sample for the present study, from 9 different centres of
seven countries, was composed of 452 patients, 55.3% males, with
age (mean ± SD) 65.1 ± 10.7 years (range: 22e91) and PD duration
8.7 ± 6.3 years (range: 0e40). HY staging was: 69 (15.3%) were in
stage 1; 163 (36.0%) in stage 2; 133 (29.4%) in stage 3; 70 (15.5%) in
stage 4; and 17 (3.8%) in stage 5. Additional characteristics of the
sample are shown in Table 2.
Concerning treatment for PD, 86.5% of patients received levo-
dopa, 57.5% dopamine agonists, 49% a combination of both; and
36.6% other anti-PD drugs such as MAOB inhibitors or amantadine.
Thirty-eight patients (8.4%) underwent functional surgery for PD.
Table 3 shows the distribution of the sample broken down by
the PD severity levels (mild, moderate, severe) derived from the HY,
CISI-PD, CGIS, and PGIS as described in the Data analysis section.
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The correlation between these scales ranged from 0.84 (CGIS with
CISI-PD levels) to 0.56 (HY with PGIS levels) and the Kendall's co-
efﬁcient of concordance among the four classiﬁcations was 0.65
(p < 0.0001). The percentage of agreement between their respec-
tive severity levels classiﬁcations ranged from 87% (HY with PGIS)
to 95% (CISI-PD with CGIS).
For a deﬁnitive classiﬁcation of patients, the “criterion of
severity”, consisting in the agreement between at least two grading
systems out of the three clinician-based (HY, CISI-PD, and CGIS)
plus the PGIS was used. The “criterion”, classiﬁed 275 patients out
of 452 (60.8% of the sample) as: mild PD, 149 (54.2%); moderate, 82
(29.8%); and severe, 44 (16%). Values of the variables in the study,
broken down according to these severity levels, are shown
in Table A (Supplementary material). All historic and evaluative
values were signiﬁcantly different between the established severity
categories.
Cut-off points for the four MDS-UPDRS sections were deter-
mined by percentile 90, ROC analysis, and OLR (Table 4). As fore-
seen, the obtained cut-off values were not coincident, although
differences between methods were only around 2e3 points. The
mean values among the three methods (triangulation) offer a
theoretical approach to the true cut-off point values (Table 4;
Supplementary material, Figs. 1 and 2).
4. Discussion
Estimations about the severity of a chronic disease are neces-
sary, but also may be elusive when a recognized objectivemarker of
severity does not exist. In this situation, the estimates are based on
subjective appraisal and clinical experience.
For neurodegenerative diseases and speciﬁcally for PD, the
continuum between onset and advanced phases is very variable in
the expression and rate of progression. Presence and severity of
symptoms throughout time is heterogeneous, with a wide
variability among patients, making difﬁcult to deﬁne limits for
disease severity gradation. As recently shown, a discrepancy be-
tween the gradation of motor and non-motor disorders is
commonly observed [9,18].
However, having available a consistent method for classifying
PD patients as mild, moderate, or severe would entail advantages
for a diversity of settings from daily practice to social-health policy.
Such method could be implemented on the appearance of speciﬁc
symptoms, the number of symptoms, or thresholds reached in
measures of severity or disability. Nonetheless, in the absence of a
deﬁned and appropriate anchor, the determination of cut-off values
for these measures would be arbitrary.
Using global measures has the disadvantages of subjectivity and
scant precision, but conceptually is more close to the intended
classiﬁcation. In the present study, we used a combination of this
kind of measures resulting from the patient evaluation and clinical
impression (HY, CISI-PD, CGIS) and patient self-assessment (PGIS).
The coincidence in the gradation derived from estimations coming
from both sources was considered “the criterion” to deﬁnitively
setting a case as mild, moderate, and severe, as doctors and patients
e simultaneously and independently e consider this is the severity
level to which the patient can be assigned. This coincidence was
possible in only 61% of the cases, due to the conditions imposed for
the elaboration of the criterion, but is consistent and allows the
extrapolation of the outcomes for the complete sample. It is worthy
of note that neither neurologists nor patients knew about the
intention of this study, which was conceived to this purpose but
embedded in other explicitly aimed at evaluation of disability in PD.
The Uniﬁed Parkinson's Disease Rating Scale has been the most
widely used scale to measurement impairment and disability in PD
[19]. After a careful revision of this scale, the Movement Disorders
Society sponsored its revision and the development of the MDS-
UPDRS which retains the strength of the UPDRS, adds some ele-
ments not covered by this scale, resolves ambiguities, and provides
Table 1
Parkinson's disease severity classiﬁcation based on global evaluations.
Normal Mild Moderate Severe
Clinical assessments
Hoehn and Yahr staging 0 1e2 3 4e5
Clinical Impression of Severity
Index for Parkinson's disease
0 1e7 8e14 15e24
Clinical Global Impression of Severity 1 2e3 4 5e7
Patient self-assessment
Patient Global Impression of Severity 0 1e2 3 4e5
Table 2
Characteristics of the sample.
Mean SD Median CI95% Range
Age at PD onset 56.5 11.2 57 55.50e57.58 17e80
Years since diagnosis 7.8 6.0 7 8.09e9.26 0e37
Duration of treatment 7.6 6.0 6 7.23e8.35 0e37
Education (years) 11.7 5.4 12 11.17e12.17 0e36
MDS-UPDRS 1 11.1 7.0 10 10.45e11.76 0e34
MDS-UPDRS 2 15.3 11.4 13 14.29e16.40 0e49
MDS-UPDRS 3 35.2 21.2 31 33.29e37.21 0e97
MDS-UPDRS 4 4.6 5.0 3 4.19e5.11 0e18
CISI-PD 8.4 5.1 8 7.92e8.87 0e21
Levodopa daily dose 626.0 467.8 600 582.79e669.27 0e4000
DA-LEDD 133.2 158.3 80 118.56e147.83 0e1380
Total LEDD 759.2 490.9 750 713.85e804.61 0e4000
SD: standard deviation. CI95%: conﬁdence interval 95%. PD: Parkinson's disease.
MDS-UPDRS: Movement Disorder Society-Uniﬁed Parkinson's Disease Rating Scale.
CISI-PD: Clinical Impression of Severity Index for Parkinson's disease. DA-LEDD:
dopamine-agonist levodopa-equivalent daily dose. Total LEDD: levodopa daily
dose þ Dopamine-agonist levodopa-equivalent daily dose.
Table 3
Distribution of the sample broken down by severity levels based on the applied
global evaluations.
HY CISI-PD CGIS PGIS
Mild 232 (51.3%) 222 (49.1%) 205 (45.3%) 189 (41.8%)
Moderate 133 (29.4%) 162 (35.8%) 154 (34.1%) 170 (37.6%)
Severe 87 (19.3%) 68 (15.1%) 93 (20.6%) 93 (20.6%)
HY: Hoehn and Yahr staging. CISI-PD: Clinical Impression of Severity Index for
Parkinson's disease. CGIS: Clinical Global Impression of Severity. PGIS: Patient
Global Impression of Severity.
Table 4
Cut-off points of the MDS-UPDRS.
MDS-UPDRS Method Triangulation
cut-off values
Centile 90 ROC OLR
Part 1
Mild/moderate 11/12 8/9 11.4/11.5 10/11
Moderate/severe 20/21 23/24 20.5/20.6 21/22
Part 2
Mild/moderate 12/13 12/13 13.5/13.6 12/13
Moderate/severe 28/29 30/31 29.2/29.3 29/30
Part 3
Mild/moderate 35/36 27/28 33.4/33.5 32/33
Moderate/severe 57/58 57/58 60.5/60.6 58/59
Part 4
Mild/moderate 3/4 4/5 4.5/4.6 4/5
Moderate/severe 11/12 13/14 11.4/11.5 12/13
ROC: receiver operating characteristic analysis.
OLR: ordinal logistic regression.
MDS-UPDRS: Movement Disorder Society-Uniﬁed Parkinson's Disease Rating Scale.
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detailed instructions. It includes 50 items divided in 4 non-
summative sections. Although a conceptual framework of slight/
mild/moderate/severe is offering for each individual question, such
frame of level of affectation is not offered for the numerical result of
each section. Here it is needed to be said again that neither the
UPDRS nor the MDS-UPDRS have been designed for such concep-
tual framework classiﬁcation on levels of severity.
However, in the MDS-Task Force publication on the UPDRS au-
thors stated that future goals should include the deﬁnition of scores
that correlate with clinically pertinent designations, such us
“minimal,” “mild,” “moderate,” and “severe” PD [19]. According to
this statement, the objective of the present study was to explore
whether different scores of the individual sections of the UPDRS
may suggest categorical levels of disease severity which may be of
utility at bedside use. To our knowledge, a similar gradation is not
available for the MDS-UPDRS and the present study would be,
therefore, the ﬁrst attempt for furnishing such a clinically relevant
classiﬁcation.
To have available a consistent method for classifying PD patients
as mild, moderate, or severe would entail advantages for a diversity
of settings from daily practice to social-health policy. Such method
could be implemented on the appearance of speciﬁc symptoms or
complications, number of symptoms, or threshold reached in
measures of severity or disability, but that task immediately seems
to be complex. We think that the concordance of global scores from
three clinical validated scales together with one scale of patient
self-evaluation could provide a reliable method for deﬁnition of
severity levels.
For trained clinicians is not difﬁcult to link UPDRS motor scores
to a severity stage. As an example, Lang and co-workers stated that
patients with a Part III UPDRS score of 30 or below in off stage were
not enough disabled to undergo DBS whereas scores of 30 or above
in on stage reﬂect too much affectation to be considered a candi-
date for surgery [20]. However such precision cannot be achieved
by other than experts in movement disorders and an objective limit
statistically determined would be welcome for clinical practice
daily use.
Concerning limitations of the study, future studies with other
samples and using a different approach can ﬁnd other results, but
the sample size in our study, the strength of the statistical methods
applied, and the proximity of their results are promising. Triangu-
lation, offering a balanced value among those coming from
different approaches, has a strong logical basis and has been pro-
posed in other settings sharing a similar context of uncertainty on
the authentic value among several available [21,22]. Depression is a
common and core non motor symptom in PD impacting on pa-
tients' disability and quality of life. It may be argued that depression
may affect self-assessments. However, this symptom must be
considered into the gamut of non motor manifestations contrib-
uting to the severity of the disease and cannot be excluded. To
diminish the impact of any circumstance inﬂuencing self-
evaluation the cut-off scores were obtained only on data from
coincident gradation by patient and doctor. This way, potential bias
of patient self-evaluation was discarded or attenuated.
Forty per cent of patients did not meet “the criterion of severity”
established for this study. To determine the MDS-UPDRS cut-offs
these patients could not be considered. However, once the cut-off
points are settled they can be applied to any patient assessed by
means of the MDS-UPDRS.
In conclusion, we found through the agreement between
clinician-based evaluations and patient self-assessment, a reliable
categorical classiﬁcation of PD severity (mild, moderate, severe) to
which cut-offs for MDS-UPDRS scores could be assigned by
consistent statistical methods. This way, the severity level can be
directly determined from the scores of the MDS-UPDRS subscales
and this gradation may be of clinical utility. We propose the values
shown in the column “Triangulation cut-off values” in Table 4 to
classify PD patients' condition as mild, moderate, or severe on the
basis of their MDS-UPDRS scores.
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